China unveiled the State administration for market regulation and the State Administration of Drug supervision on 10th April 2018

China unveiled the State administration for market regulation and the State Administration of Drug supervision on 10th April 2018

According to the report of Xinhua News Agency, under the witness of Mr. Wang Yong, the State Councilor, the office of State administration for market regulation unveiled the official address at the address of No. 8 Sanlihe East Road, Xicheng District, Beijing at 9:30am on 10th April 2018.
The original CFDA’s food safety supervision function was fully assigned to other new Bureaus. Taking into account the special situation of the supervision of pharmaceuticals (medical devices, cosmetics), the State Administration of Drug supervision was established and managed by the State administration for market regulation.
The main responsibility of the State Administration of Drug supervision is to be responsible for the registration of pharmaceuticals, cosmetics and medical devices and to implement supervision and management.
In accordance with the previously defined leadership, Bi Jingquan, an incisive proponent of China’s drug reform (approval of comprehensive reforms), was transferred to the party secretary of the State administration for market regulation. He will cooperate with the director Zhang Mao (former director of the State Administration for Industry and Commerce) to promote supervision of the big market.
In the future, the “head” of State Administration of Drug supervision will be Party Secretary Li Li (former vice governor of Jiangxi Province) and Director Jiao Hong (former Deputy Director of CFDA).
This is only the first step in the formal establishment of the State administration for market regulation. According to the spirit of the former General Administration Director Zhang Mao’s idea, there was a hang-up. The original work still needs to be done because the new three-phase plan has not been finalized. And they will implement the new San Ding plan in September 2018 and accepted it at the end of this year.

We will continue to pay attention to this new information, and we’ll keep you posted on significant developments in the coming future!

THE INFORMATION SOURCES USED
The official website of the State administration for market regulation:http://samr.saic.gov.cn/
The official website of the State Administration of Drug supervision:http://cnda.cfda.gov.cn/WS04/CL2042/#
The official website of CFDA:http://samr.cfda.gov.cn/WS01/CL0001/

No Comments

Post A Comment